Toll-like receptors (TLRs) were originally identified as receptors for exogenous pathogens, initiating the inflammatory response by immune cells. TLRs initiate downstream signaling to activate the key transcription factor, NF-κB, producing inflammatory cytokines (1). More recently, however, their role in noninfectious insults such as ischemia–reperfusion has been highlighted (2), which is referred to as sterile inflammation. In sterile inflammation, antigen-presenting cells are activated by molecules released from injured self-cells, known as damage-associated molecular patterns (DAMPs), and switch on the inflammatory response. Importantly, TLRs are the major DAMP receptors (3).

Among TLRs, TLR9 is the sole family member for detecting DNA (4). TLR9 was originally found as a sensor for bacterial DNA (4). TLR9 was originally found as a sensor for bacterial DNA and the change in energy substrates was completely abrogated in TLR9−/− mice (Fig. 1A and B), indicating that the observed metabolic effect was mediated through TLR9.

To further explore whether the AMPK activation observed in the whole heart occurred in cardiomyocytes, we studied primary neonatal cardiomyocytes that also expressed TLR9 (Fig. S1B). The increased phosphorylation of AMPK in response to CpG-ODN (type B) was confirmed in these cardiomyocytes, but not in cardiac fibroblasts (a major contaminant of primary cardiomyocyte cultures) (Fig. 1C). Type A CpG-ODN also activated AMPK in cardiomyocytes (Fig. 1C), indicating that the AMPK activation is independent of CpG-ODN type (CpG-ODN type B was used throughout the remainder of the study). A time-course analysis

Here we uncover a unique TLR9 signaling pathway that modulates energy metabolism to protect cardiomyocytes and neurons, independent of the canonical inflammatory signaling. Furthermore, our data suggest Unc93b1, a key TLR9-trafficking molecule, is a pivotal switch for the distinct TLR9 responses.

**Results**

**TLR9 Reduces Energy Substrates in Cardiomyocytes with Activation of AMP-Activated Kinase, Leading to Increased Stress Tolerance.** First, to confirm the role of TLR9 to reduce contractility, we compared ex vivo crystalloid-perfused, beating hearts from wild-type and TLR9−/− mice using the Langendorff method, which enabled us to eliminate the effect from circulating immune cells. Consistent with the earlier report using isolated cardiomyocytes in vitro (8), CpG oligodeoxynucleotides (CpG-ODN; a synthetic TLR9 ligand) significantly decreased cardiac contractility through TLR9 as early as 20 min following its administration without changing coronary flow (Fig. S1A). As nitric oxide and some volatile anesthetics suppress the cardiac contractility with reducing energy metabolism (9), we next measured energy substrates in the heart. Interestingly, the wild-type heart with CpG-ODN showed marked decreases in the ATP/ADP and creatine phosphate/creatine ratios (both of which are indicators for energy metabolism in cardiomyocytes) and an increase in the AMP/ATP ratio (Fig. 1A). An increased AMP/ATP ratio is the key trigger for activation of AMP-activated kinase (AMPK) (10, 11). AMPK activation switches off ATP-consuming processes that are not essential for short-term cell survival to increase the cellular tolerance against the metabolic stress (12–14). Indeed, the administration of CpG-ODN increased the phosphorylation of AMPK and its substrate, acetyl-CoA carboxylase (ACC), in the wild-type heart (Fig. 1B). Both AMPK activation and the change in energy substrates were completely abrogated in TLR9−/− mice (Fig. 1A and B), indicating that the observed metabolic effect was mediated through TLR9.

**Toll-like (TLR) and intracellular receptors (ICRs)**

**Artemisinin**

**RESULTS**

**TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons**

Yasunori Shintani1,1, Amar Kapoor*, Masahiro Kaneko*, Ryszard T. Smolenski†, Fulvio D’Acquisto†, Steven R. Coppen**, Narumi Harada-Shojii, Hack Jae Lee*, Christoph Thiemermann*, Seiji Takashima*, Kenta Yashiro†, and Ken Suzuki*1

*William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E15 6BH, United Kingdom; †Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland; and ‡Department of Molecular Cardiology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan

Edited* by Ruslan Medzhitov, Yale University School of Medicine, New Haven, CT, and approved February 15, 2013 (received for review November 6, 2012)

Toll-like receptors (TLRs) are the central players in innate immunity. In particular, TLR9 initiates inflammatory response by recognizing DNA, imported by infection or released from tissue damage. Inflammation is, however, harmful to terminally differentiated organs, such as the heart and brain, with poor regenerative capacity, yet formation is, however, harmful to terminally differentiated organs, such as the heart and brain, with poor regenerative capacity, if TLR9 in nonimmune organs with poor regenerative capacity, yet organs with poor regenerative capacity, if TLR9 in nonimmune cells operated the same in differentiated neuronal cells. These data propose an intriguing model that the same ligand operates in differentiated neuronal cells. Furthermore, this alternative TLR9 signaling was also found to increase the stress tolerance in cardiomyocytes and neurons. TLR9 stimulation reduced energy substrates and increased AMP/ATP ratio, subsequently activating AMP-activated kinase (AMPK), leading to increased stress tolerance against hypoxia in cardiomyocytes without inducing the canonical inflammatory response. Analysis of the expression profiles between cardiomyocytes and macrophages identified that unc93 homolog B1 (C. elegans) was a pivotal switch for the distinct TLR9 responses by regulating subcellular localization of TLR9. Furthermore, this alternative TLR9 signaling was also found to operate in differentiated neuronal cells. These data propose an intriguing model that the same ligand–receptor can concomitantly increase the stress tolerance in cardiomyocytes and neurons, whereas immune cells induce inflammation upon tissue injury.

Edited* by Ruslan Medzhitov, Yale University School of Medicine, New Haven, CT, and approved February 15, 2013 (received for review November 6, 2012)

Toll-like receptors (TLRs) are the central players in innate immunity. In particular, TLR9 initiates inflammatory response by recognizing DNA, imported by infection or released from tissue damage. Inflammation is, however, harmful to terminally differentiated organs, such as the heart and brain, with poor regenerative capacity, yet formation is, however, harmful to terminally differentiated organs, such as the heart and brain, with poor regenerative capacity, if TLR9 in nonimmune organs with poor regenerative capacity, if TLR9 in nonimmune cells operated the same in differentiated neuronal cells. These data propose an intriguing model that the same ligand operates in differentiated neuronal cells. Furthermore, this alternative TLR9 signaling was also found to increase the stress tolerance in cardiomyocytes and neurons, whereas immune cells induce inflammation upon tissue injury.

Here we uncover a unique TLR9 signaling pathway that modulates energy metabolism to protect cardiomyocytes and neurons, independent of the canonical inflammatory signaling. Furthermore, our data suggest Unc93b1, a key TLR9-trafficking molecule, is a pivotal switch for the distinct TLR9 responses.

**Results**

**TLR9 Reduces Energy Substrates in Cardiomyocytes with Activation of AMP-Activated Kinase, Leading to Increased Stress Tolerance.** First, to confirm the role of TLR9 to reduce contractility, we compared ex vivo crystalloid-perfused, beating hearts from wild-type and TLR9−/− mice using the Langendorff method, which enabled us to eliminate the effect from circulating immune cells. Consistent with the earlier report using isolated cardiomyocytes in vitro (8), CpG oligodeoxynucleotides (CpG-ODN; a synthetic TLR9 ligand) significantly decreased cardiac contractility through TLR9 as early as 20 min following its administration without changing coronary flow (Fig. S1A). As nitric oxide and some volatile anesthetics suppress the cardiac contractility with reducing energy metabolism (9), we next measured energy substrates in the heart. Interestingly, the wild-type heart with CpG-ODN showed marked decreases in the ATP/ADP and creatine phosphate/creatine ratios (both of which are indicators for energy metabolism in cardiomyocytes) and an increase in the AMP/ATP ratio (Fig. 1A). An increased AMP/ATP ratio is the key trigger for activation of AMP-activated kinase (AMPK) (10, 11). AMPK activation switches off ATP-consuming processes that are not essential for short-term cell survival to increase the cellular tolerance against the metabolic stress (12–14). Indeed, the administration of CpG-ODN increased the phosphorylation of AMPK and its substrate, acetyl-CoA carboxylase (ACC), in the wild-type heart (Fig. 1B). Both AMPK activation and the change in energy substrates were completely abrogated in TLR9−/− mice (Fig. 1A and B), indicating that the observed metabolic effect was mediated through TLR9.

To further explore whether the AMPK activation observed in the whole heart occurred in cardiomyocytes, we studied primary neonatal cardiomyocytes that also expressed TLR9 (Fig. S1B). The increased phosphorylation of AMPK in response to CpG-ODN (type B) was confirmed in these cardiomyocytes, but not in cardiac fibroblasts (a major contaminant of primary cardiomyocyte cultures) (Fig. 1C). Type A CpG-ODN also activated AMPK in cardiomyocytes (Fig. 1C), indicating that the AMPK activation is independent of CpG-ODN type (CpG-ODN type B was used throughout the remainder of the study). A time-course analysis

**Author contributions:** Y.S. designed research; Y.S., M.K., A.K., R.T.S., N.H.-S., and H.J.L. performed research; F.D., C.T., and S.T. contributed new reagents/analytic tools; Y.S., F.D., S.R.C., S.T., K.Y., and K.S. analyzed data; and Y.S. and K.S. wrote the paper.

The authors declare no conflict of interest.

*This Direct Submission article had a prearranged editor.

F4 allergy are widely available online through the PNAS open access option.

1To whom correspondence may be addressed. E-mail: y.shintani@qmul.ac.uk or ken.suzuki@qmul.ac.uk.

This article contains supporting information online at www.pnas.org/cgi/content/full/1219243110/DCSupplemental.
but not in TLR9
increased the AMP/ATP ratio in ex vivo perfused heart in wild-type (WT) mice, control. The data represent two independent experiments. (A)

Cardiomyocytes. Oligomycin A (10 μM), abrogated the protective effect of CpG-ODN (Fig. 1F), suggesting that AMPK is a mediator of the protective effect of TLR9.

Unique TLR9 Signaling in Cardiomyocytes Is Independent of Myeloid Differentiation Primary Response Gene 88 (MyD88). Next, to test whether the canonical inflammatory TLR9 signaling operates in cardiomyocytes, we compared the TLR9 response between RAW264.7 cells (a macrophage cell line) and cardiomyocytes. The inflammatory TLR9 response [i.e., IκBα degradation and phosphorylation (Fig. 1C and Fig. S2A), 38 MAPK phosphorylation (Fig. 1C), NF-κB [p65 subunit] nuclear translocation (Fig. S2A), and NF-κB electrophoretic mobility shift assay (Fig. S2B), NF-κB luciferase assay (Fig. S2E), and cytokine production (Fig. S2F)] was detected in RAW264.7 cells, but not in cardiomyocytes after CpG-ODN administration. In contrast, the phosphorylation of AMPK increased in cardiomyocytes, but not in RAW264.7 cells (Fig. 1C). These results suggest that the TLR9 signaling in cardiomyocytes is different from the canonical TLR9 signaling pathway in immune cells.

As the canonical inflammatory TLR9 signaling is mediated by a common TLR adaptor molecule, MyD88 (1), we next examined MyD88 involvement in the CpG-induced AMPK activation in cardiomyocytes by using MyD88−/− mice and MyD88 knockdown. The CpG-mediated AMPK activation was not affected in the neonatal cardiomyocytes by MyD88−/− mice (Fig. 1G) or by Myd88 knockdown in rat cardiomyocytes (Fig. S1D). These data suggest that the alternative TLR9 signaling in cardiomyocytes is different from the canonical TLR9 signaling in immune cells.

Unc93b1 Is a Pivot Switch for the Distinct TLR9 Responses in Cardiomyocytes and Macrophages. To gain an insight into the mechanism by which the different TLR9 responses occur between cardiomyocytes and RAW264.7 macrophages, we performed RT-PCR screening for the known TLR9 signaling molecules. The results showed that Unc93b1 was significantly less expressed in cardiomyocytes than in RAW264.7 cells (Fig. 2A and Fig. S2A). Unc93b1 is the key molecule for TLR9 trafficking from the endoplasmic reticulum (ER) to the endosome/lysosomes and its cleavage (20). In macrophages and dendritic cells, the majority of TLR9 exists in the ER, whereas a minor fraction is present in the endosomes under resting condition (20, 21). After stimulation, TLR9 translocates to the endosome/lysosome compartment where MyD88 and the subsequent molecular complex initiate inflammatory signaling. Recently it was found that TLR9 ectodomain is cleaved in the endosome compartment, creating a C-terminal cleaved form (80 kDa) (22–25). Although both full-length (150

unique TLR9 signaling in cardiomyocytes. Mitochondrial DNA (descended from bacterial DNA) is rich in unmethylated CpGs and is therefore a potent ligand for TLR9 (15). As cardiomyocytes possess abundant mitochondria (16), it is likely that higher amounts of this would be released in the heart during tissue damage than in other tissues. Indeed, mitochondrial DNA induced AMPK activation in cardiomyocytes in the same manner as synthetic CpG-ODN (Fig. S1C).

As the heart has low regenerative capacity, it is vital to protect many surviving cardiomyocytes as possible from damaging inflammation. Therapeutic hypothermia has been shown to protect the heart and brain from injury by slowing metabolism and by switching on survival pathways (17). Also, well-known cardioprotective reagents including volatile anesthetics, nitric oxide, and beta blockers, reduce cardiac contractility, which is considered to be a part of the mechanism of cardioprotection (9). In addition, there are several lines of evidence showing that the activation of AMPK is cardioprotective (18, 19). Given our observation that TLR9 induced a negative inotropic effect with subsequent AMPK activation, we hypothesized that TLR9 exerts a protective effect in cardiomyocytes. Indeed, pretreatment with CpG-ODN significantly increased the cardiomyocyte survival against hypoxia compared with the vehicle control (Fig. 1F).

AMPK inhibitor, compound C (1 μM), abrogated the protective effect of CpG-ODN (Fig. 1F), suggesting that AMPK is a mediator of the protective effect of TLR9.

The in vivo perfused heart in wild-type (WT) mice, but not in TLR9−/− mice. The hearts (n = 6 for WT, n = 5 for TLR9−/−) were analyzed at 30 min after the administration of CpG-ODN (type B, 0.25 μg/mL) or vehicle (con). (B) CpG-ODN increased the phosphorylation of AMPK and its substrate, ACC, without a decrease in IκBα in ex vivo perfused heart in WT mice, but not in TLR9−/− mice. (C) CpG-ODN (type B at 3 μM or type A at 1 μM) activated AMPK 60 min after administration in cultured cardiomyocytes (CM), but not in RAW264.7 macrophages (RAW) or in cardiac fibroblasts (CFb). In contrast, the phosphorylation of p38 MAPK and a decrease in IκBα were seen in RAW264.7, but not in cardiomyocytes. The data represent four independent experiments. (D) Time-course of AMPK activation by CpG-ODN in cardiomyocytes. Oligomycin A (10 μg/mL for 60 min) was used as a positive control. The data represent two independent experiments. (E) The change in intracellular ATP levels in cardiomyocytes treated with CpG-ODN using luminescence-based measurement (n = 3). The data represent two independent experiments. (F) Pretreatment with CpG-ODN (30 min before 16 h of hypoxia, n = 6–8) increased the survival of cardiomyocytes against hypoxia. AMPK inhibitor, compound C (1 μM), abrogated the protective effect of CpG-ODN. Cell viability was normalized with normoxia control. The data represent three independent experiments. (G) The CpG-mediated AMPK activation was not affected in the neonatal cardiomyocytes from MyD88−/− mice. The data represent three independent experiments. Values indicate densitometric ratio of pAMPK/AMPK or tubulin in immunoblots, mean ± SEM. Error bars indicate SEM. *P < 0.05; **P < 0.01; ***P < 0.001 compared with control.

shown that the AMPK activation started at 30 min, reached its peak at 60 min, and subsequently recovered (Fig. 1D), suggesting that the ATP decrease by TLR9 stimulation was a transient response. We further confirmed the decrease and time course of intracellular ATP levels in cardiomyocytes using a luminescence-based measurement (Fig. 1E). To extend our findings with CpG-ODN, we next tested if mitochondrial DNA could induce the

Cell viability

Fig. 1. TLR9 reduces energy substrates with activation of AMPK independent of MyD88, leading to increased stress tolerance in cardiomyocytes. (A) Administration of CpG-ODN reduced the level of energy substrates and increased the AMP/ATP ratio in ex vivo perfused heart in wild-type (WT) mice, but not in TLR9−/− mice. The hearts (n = 6 for WT, n = 5 for TLR9−/−) were analyzed at 30 min after the administration of CpG-ODN (type B, 0.25 μg/mL) or vehicle (con). (B) CpG-ODN increased the phosphorylation of AMPK and its substrate, ACC, without a decrease in IκBα in ex vivo perfused heart in WT mice, but not in TLR9−/− mice. (C) CpG-ODN (type B at 3 μM or type A at 1 μM) activated AMPK 60 min after administration in cultured cardiomyocytes (CM), but not in RAW264.7 macrophages (RAW) or in cardiac fibroblasts (CFb). In contrast, the phosphorylation of p38 MAPK and a decrease in IκBα were seen in RAW264.7, but not in cardiomyocytes. The data represent four independent experiments. (D) Time-course of AMPK activation by CpG-ODN in cardiomyocytes. Oligomycin A (10 μg/mL for 60 min) was used as a positive control. The data represent two independent experiments. (E) The change in intracellular ATP levels in cardiomyocytes treated with CpG-ODN using luminescence-based measurement (n = 3). The data represent two independent experiments. (F) Pretreatment with CpG-ODN (30 min before 16 h of hypoxia, n = 6–8) increased the survival of cardiomyocytes against hypoxia. AMPK inhibitor, compound C (1 μM), abrogated the protective effect of CpG-ODN. Cell viability was normalized with normoxia control. The data represent three independent experiments. (G) The CpG-mediated AMPK activation was not affected in the neonatal cardiomyocytes from MyD88−/− mice. The data represent three independent experiments. Values indicate densitometric ratio of pAMPK/AMPK or tubulin in immunoblots, mean ± SEM. Error bars indicate SEM. *P < 0.05; **P < 0.01; ***P < 0.001 compared with control.
kDa) and cleaved forms can bind CpG DNA (22), only the cleaved form exists in endosomes (phagosome) and this cleavage is required/sufficient for recruiting MyD88 to its intracellular domain to initiate inflammatory signaling (25).

To test if the expression level of Unc93b1 is a deciding factor for the different TLR9 responses, we first analyzed the molecular weight of TLR9 and its association with MyD88 in both cardiomyocytes and macrophages. The molecular weight of overexpressed TLR9 in cardiomyocytes was 150 kDa, which corresponds to the full-length form, and we could not detect the cleaved form of TLR9, whereas on the other hand both full-length and cleaved forms were observed in RAW264.7 cells (Fig. 2B, Left). The interaction between TLR9 and MyD88 was found in RAW264.7 cells, whereas in contrast, it was not detected in cardiomyocytes (Fig. 2B, Right). These results further confirmed that the alternative TLR9 signaling in cardiomyocytes is independent of MyD88.

We next tested whether RAW264.7 macrophages would behave similarly to cardiomyocytes when Unc93b1 is inhibited. Of note, the knockdown of Unc93b1 by shRNA reduced the inflammatory response upon CpG-ODN stimulation and instead AMPK activation occurred in RAW264.7 cells (Fig. 2C and Fig. S3 B and C). Conversely, the overexpression of Unc93b1 in cardiomyocytes diminished TLR9-induced AMPK activation and instead switched on the inflammatory TLR9 signaling. Unc93b1 overexpressing cardiomyocytes showed the cleaved form of TLR9, association between TLR9 and MyD88, degradation of IκBα, and subsequent cytokine production (Fig. 2D–F), as seen in RAW264.7 cells.

Next we examined subcellular localization of TLR9 in cardiomyocytes. Unlike the translocation from the ER to endosomes/lysosomes that has been reported in dendritic cells and macrophages (21), TLR9 stayed in the ER and did not translocate to the endosome compartment in cardiomyocytes before and after CpG-ODN stimulation (Fig. 3A and B). In contrast, Unc93b1 overexpression transformed the trafficking of TLR9 to early endosome antigen 1 (EEA1)-positive endosomes on CpG-ODN stimulation in cardiomyocytes (Fig. 3C), including an observation that a fraction of TLR9 localized in the endosome compartment before CpG-ODN stimulation (Fig. 3C), as previously reported in immune cells (20, 21).

Exogenous DNA Translocates to the ER to Bind TLR9 via Retrograde Transport in Cardiomyocytes. The results above raised a question of whether the endocytosed DNA really comes into contact with TLR9 in the ER to facilitate the alternative TLR9 signaling in cardiomyocytes, although it has been reported that DNA binds to the cleaved form of TLR9 in the endosome in immune cells (25). To answer this question, we investigated the localization of endocytosed DNA in cardiomyocytes using biotin-labeled CpG-ODN. Notably, it was found that CpG-ODN localized in the ER (Fig. 4A) 30 min after the administration of CpG-ODN. To exclude the possibility of detecting endogenous biotin, we confirmed the same pattern of localization by using FITC-labeled CpG-ODN (Fig. S4B, Upper), which was distinct from the punctate pattern of endocytosed DNA in RAW264.7 cells (Fig. S4A and B), which is consistent with the previous report (21).

Exit from the endosomal compartment toward Golgi and ER is termed as retrograde transport and it has been reported that a retrograde transport route in cardiomyocytes is used (26). To elucidate this, we used Retro-2, an inhibitor for the retrograde transport without affecting endocytosis (27). Pretreatment with Retro-2 significantly changed the localization of endocytosed CpG-ODN (Fig. 4B). The speckled accumulation of endocytosed CpG-ODN was overlapped with EEA1-positive endosomes, indicating that cardiomyocytes indeed use the retrograde transport route for exogenous DNA. To support this, Retro-2 indeed reduced the TLR9-mediated AMPK activation in cardiomyocytes (Fig. 4C). Interestingly, Retro-2 also inhibited the CpG-ODN–induced AMPK activation in the Unc93b1 knocked-down RAW264.7 cells (Fig. 4D). Although the distribution of biotin-labeled CpG-ODN (green) in control RAW264.7 cells was a punctate pattern, it became spread and less punctate in Unc93b1 knocked-down RAW264.7 cells (Fig. S5 A and B). These data suggest that expression level of Unc93b1 affects the trafficking of endocytosed DNA and TLR9. We speculate that preexistence of TLR9 at the endosome and following supply from the ER after stimulation (20, 21, 28) (in control RAW or Unc93b1-overexpressing cardiomyocytes shown in Fig. 3C) enables...
with confocal microscopy. Experiments were repeated at least twice and the expression transformed the trafficking of TLR9 in cardiomyocytes. Please note that part of TLR9 existed in the endosome before stimulation. The cardiomyocytes, which were transfected with the adenoviruses encoding TLR9-HA-Flag (*A*), did not translocate to the endosome compartment (EEA1; red) in cardiomyocytes regardless of before and after CpG-ODN stimulation. (*B*). Unc93b1 overexpression transformed the trafficking of TLR9 to EEA1-positive endosomes in cardiomyocytes. Please note that part of TLR9 existed in the endosome compartment before stimulation. The cardiomyocytes, which were transfected with the adenoviruses encoding TLR9-HA-Flag (*A*–*C*) and Unc93b1 in (*C*), were stimulated by CpG-ODN. (Scale bars, 10 μm.) Images were obtained with confocal microscopy. Experiments were repeated at least twice and the representative images are shown.

The majority of endocytosed DNA was trapped by TLR9 at the endosome, resulting in the initiation of the canonical inflammatory signaling. In contrast, very little existence of TLR9 at the endosome regardless of before and after CpG-ODN stimulation. In the retrograde transport system, exerting the alternative TLR9 signaling (Fig. 5B). CpG-ODN stimulation significantly increased TLR9 expression level of Unc93b1 expression will allow DNA to travel to the ER via the retrograde transport system, exerting the alternative TLR9 signaling (Fig. 5E). Collectively, we conclude that exogenous DNA translocates to the ER via the retrograde transport to bind TLR9 in cardiomyocytes.

**Alternative TLR9 Signaling also Operates in Differentiated Neuronal Cells.** We further investigated whether the alternative TLR9 signaling in cardiomyocytes is applicable to other nonimmune cells more generally. To examine this, we used human SH-SY5Y cells, which after substantial treatment with retinoic acid and BDNF yielded terminally differentiated neuronal cells (29). Although undifferentiated SH-SY5Y cells showed only a subtle increase in phosphorylated AMPK after CpG-ODN stimulation, the differentiated neuronal cells demonstrated a robust and transient increase in phosphorylated AMPK without any degradation of IkBα (Fig. 5A). CpG-ODN stimulation significantly decreased intracellular ATP levels in the differentiated neuronal cells (Fig. 5B). We also found the endocytosed CpG-ODN localized in the ER (Fig. S4). These data suggest that the same alternative TLR9 signaling we observed in cardiomyocytes also operates in neuronal cells. Compared with human monocytes/macrophages, the expression level of Unc93b1 remained low in SH-SY5Y cells regardless of the differentiation status, whereas Tlr9 expression significantly increased in the differentiated neuronal status (Fig. 5C), which might account for the different extent of the unique TLR9 responses between two differentiation states. Finally, the pretreatment with CpG-ODN decreased cell death and increased cell viability after hydrogen peroxide insult in the differentiated neuronal cells (Fig. 5D).

**Discussion**

In this study, we revealed an unexpected role of TLR9 in energy metabolism and cellular protection in not only cardiomyocytes but also in neuronal cells. Importantly, the alternative TLR9 signaling in these cells is independent of the canonical inflammatory signaling in immune cells, although the two pathways are interchangeable by the expression level of Unc93b1.

On the basis of these findings, we propose an intriguing model of biological adaptation, in which nonimmune cells with lower expression levels of Unc93b1 will sense the danger signal from damaged cells upon injury, reduce energy consumption, and consequently increase the stress tolerance through AMPK activation, whereas immune cells with higher expression of Unc93b1 initiate an inflammatory response (Fig. 5E). The concept that the same ligand–receptor in innate immunity can concomitantly increase the stress tolerance in cardiomyocytes and neurons, whereas immune cells induce inflammation upon tissue injury, will shed alternative light on our understanding of innate immunity.

One important finding in our study is that Unc93b1 is the pivotal switch for the distinct TLR9 responses. Also we found that the alternative TLR9 signaling in neuronal cells is independent of MyD88. Thus, a strategy to dissect innate immune responses between immune and nonimmune cells will synergistically induce a protective effect against tissue injury: enhancing the self-protective TLR9 signaling in cardiomyocytes and neurons, concurrently with the systemic inhibition of Unc93b1 or MyD88, which could achieve effective attenuation of damaging inflammation, may have clinical implication.

Furthermore, our study may have an implication in chronic inflammation, which is a major pathogenesis/modulator for a wide range of diseases, such as heart failure, neurodegenerative diseases, and metabolic syndrome. Dysregulation of the response to endogenous ligands is known to be important for sustaining chronic inflammation in metabolic syndrome (30). Our data showed that the expression level of Unc93b1 is the deciding factor for the distinct TLR9 signaling pathways; hence, altered expression of Unc93b1 can transform TLR9 signaling from protective to inflammatory in nonimmune cells in pathological conditions.

Recently Oka et al. reported mitochondrial DNA that escapes from degradation in the lysosome can trigger an inflammatory response in cardiomyocytes in pressure-overloaded heart (31). Discrepancy in our observation and theirs may be caused by the different status of cardiomyocytes; healthy or under the pathologic condition of pressure overload. Pressure overload heavily induces oxidative stress in cardiomyocytes and alters the gene expression profile with significant epigenetic modulation (32–34). It may lead to altered Unc93b1 expression, enabling cardiomyocytes to induce canonical inflammatory signaling in response to mitochondrial DNA, as we observed in Unc93b1 overexpressing cardiomyocytes.

Another possibility is the difference in transport route for DNA, as we observed in undifferentiated SH-SY5Y cells: although our model using exogenous DNA; although our finding that endocytosed DNA reached the ER via retrograde transport system was based on the experiment using a single inhibitor. Further study, e.g., specific knockdown of members of the retromer complex, would be required to conclusively demonstrate this transport route. Nevertheless, future investigation of the TLR9 signaling in cardiomyocytes under pathological conditions is warranted and may provide better understanding of these diseases and alternative therapeutic options.

In this manuscript, we found the alternative TLR9 signaling that reduces energy substrates to protect cardiomyocytes and neurons by activating AMPK. There are two possibilities for the decrease in energy substrates (intracellular ATP levels): either an...
increase in energy expenditure or a decrease in ATP synthesis. Considering that we observed decreased contraction throughout the ex vivo heart experiment, it is unlikely to be caused by increased energy expenditure, rather a decrease in ATP synthesis.
would be a more probable explanation. A brief episode of reversible ischemia before the prolonged ischemia induces powerful tissue protection, referred to as ischemic preconditioning (IPC) (35). Interestingly, IPC reduces mitochondrial ATP synthesis during IPC; however, it prevents further decrease in intracellular ATP under sustained ischemia. Also it has been known that a number of drugs, which reversibly inhibit mitochondrial metabolism, improve recovery from ischemia reperfusion injury (9).

It is an intriguing concept that an endogenous molecule, DNA, is released from damaged cells upon tissue injury, induces energy starvation to switch on cellular protective machinery in non-immune cells, e.g., cardiomyocytes and neurons. Further research is needed to understand the mechanism by which TLR9 in the ER reduces inflammation matrices were purchased from Sigma. 

Materials and Methods

Mice and Reagents. TLR9−/− and MyD88−/− mice were generated in Shizuo Akira’s laboratory (Osaka University, Osaka) and purchased from Oriental Kobo with C57BL6 background (Kyoto). C57BL6 wild-type mice were obtained from Charles River. CpG-ODN 2216 (CpG type A), CpG-ODN 1668 (CpG type B), FITC-labeled CpG-ODN 1668, biotin-labeled CpG-ODN 1826 (CpG type B), TLR2 ligand (HKL), TLR4 ligand (LPS-EB Ultrapure) and TLR7 ligand (imiquimod) were purchased from Sigma. Compound C and Retro-2 were purchased from Merck, Oligomycin A was purchased from Sigma. ER tracker red was purchased from Invitrogen.

Antibodies. Antibodies for SERCA2 (Abcam; ab3625), phosho-AMPK (Cell Signaling; 2535), AMPK (Cell Signaling; 2532), phosho-ACC (Cell Signaling; 3861), ACC (Cell Signaling; 3676), phosho-IκBα (Cell Signaling; 9246), IκBα (Cell Signaling; 9242), NF-κB (653) (Cell Signaling; 4764), EEA-1 (Cell Signaling; 2411), tubulin (Sigma; B-5-1-2), HA (Roche; 31F0), phosho-p38MAPK (Cell Signaling; 9216), and MyD88 (Abcam; ab2064) were purchased as presented. Anti-Flag (M2) affinity matrices were purchased from Sigma.

Cell Culture. Primary cultures of neonatal rat cardiomyocytes were prepared from 2- to 3-d-old Wistar rats. Harvested hearts were incubated in 0.25% trypsin/EDTA (Sigma) at 4 °C overnight and then digested with collagenase type II (Worthington). The cardiomyocyte fraction was collected after differential centrifugation of other cell types contaminating the culture. Cells were normally used 6 d after isolation. The medium was changed to DMEM containing 2% FBS for 30 min before CpG-ODN administration. For Ca2+ transient and mitochondrial Ca2+ experiments, media were supplemented with 3.6 mM Ca2+. RAW264.7 cells were obtained from European Collection of Cell Culture (ECACC) and maintained in DMEM supplemented with 10% FBS. The SH-SYSY human neuroblastoma cells were obtained from ATCC and maintained in DMEM/F12 supplemented with 10% FBS. For differentiation, cells were seeded at an initial density of 104 cells/ml in culture dishes. All-transretinoic acid (RA) (Sigma) was added the day after plating at a final concentration of 10 μM in DMEM/F12 with 2% FBS. After 5 d in the presence of RA, the cells were washed with DMEM/F12 and incubated with 50 ng/ml BDNF (Peptech) in DMEM/F12 without serum for 3 d (29). Before experiments, the medium was replaced with neurobasal medium (Invitrogen) with B27 supplement (Invitrogen). U937 cells were obtained from ECACC and maintained in RPMI supplemented with 10% FBS. For differentiation to the macrophage phenotype, the cells were treated with 10 nM PMA for 16 h, then incubated with RPMI supplemented with 10% FBS for 3 d.

Further methods and additional discussion are found in SI Discussion 1, SI Discussion 2, and SI Materials and Methods.

ACKNOWLEDGMENTS. We thank Melanie M. Brinkmann for the mTLR9-myc construct; Paul Chapelle for SH-SYSY cells; Hannes C. A. Drexler, Cesare M. N. Terracciano, Hiromi Imamura, Hidetaka Kioka, Shizuo Akira, Osamu Takeuchi, Kinya Otsu, and Masaharu Akao for help and suggestions on this project; and members of the K. S. laboratory. This research was supported by the New Investigator Research Grant from the Medical Research Council (G1000461 to Y. S.), the Barts and the London Charity, and the National Institute for Health Research Cardiovascular Biomedical Research Unit. Y. S. is also supported by the Uehara Memorial Foundation.

**Supporting Information**

**Shintani et al. 10.1073/pnas.1219243110**

**SI Discussion 1**

Recently, Knuefermann et al. reported that Toll-like receptor 9 (TLR9)-mediated NF-κB nitric oxide synthase 2 (NOS2) induction and negative inotropic effect were observed 4 h, but not in the first 1–3 h, after administration of CpG-oligodeoxynucleotides (CpG-ODN) in isolated mouse adult cardiomyocytes (1). In contrast, we used neonatal cardiomyocytes from rat and mouse (Fig. 1 C, D, and G) and did not observe any NF-κB activation at earlier time points (30–60 min) and up until 3 h.

The major difference between our findings and their findings is the time course analyzed. This can be well explained by the class II characteristics of NOS2 induction after TLR stimulation (2). The previous extensive research demonstrated that, even though NF-κB activation occurs at early time points, TLRs (NF-κB) target genes are classified into three groups; primary response genes (class I), secondary response genes (class II), and tertiary response genes (class III) (2). NOS2 is one of the most extensively studied target genes and well classified as a class II gene, which are up-regulated 2–6 h after stimulation because they require de novo protein synthesis of cofactors including the class I genes (3). Therefore, it is unlikely that rapid NOS2 induction occurs within the time frame of 30–60 min after stimulation.

In relevance to this issue, to exclude the possibility of NO induction via activation of any NOS member without transcription in cardiomyocytes at the time point we focused on, we tested the effect of nonspecific NOS inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), and heparinized (heparin sodium, 1 IU/g of BW, intraperitoneally) and heparinized (heparin sodium, 1 IU/g of BW, intraperitoneally). Following a thoracotomy, the heart was excised and rapidly transferred to ice-cold Krebs–Henseleit buffer (KHB), containing (in millimoles) NaCl 118, KCL 3.8, MgSO4 1.19, NaHCO3 25, CaCl2 1.25, KH2PO4 1.18, sodium pyruvate 5, and glucose 10; equilibrated with 95% O2/5% CO2 (pH 7.4). Aortic cannulation was performed (within 1 min of excision), and hearts were perfused with filtered KHB gassed continuously with 95% O2/5% CO2 and maintained at 37 °C. Hearts were retrogradely perfused in a recirculating Langendorff mode. Coronary flow was monitored and adjusted using a flow meter to achieve a coronary perfusion pressure of 75 ± 5 mmHg. Hearts were allowed to stabilize for at least 15 min before any experimental protocols were carried out. A handmade balloon connected to a polyethylene tube was inserted into the left ventricle (LV) through the mitral valve via an incision in the left atrium and was connected to a pressure transducer (AD Instruments). Recorded waveforms were analyzed using chart 5 (AD Instruments) and maximal rate of pressure rise (LV dp/dt max) were calculated from the average of at least 50 cardiac cycles. LV dp/dt max is a reasonable index of the contractile ability of the heart.

**SI Discussion 2**

To answer whether our findings are specific to TLR9 or not, we checked the response to stimulation of TLR2, -4 (cell surface TLRs), and also TLR7 (nucleotide sensing, an ER endosome). Whereas TLRs, it is likely that the similar mechanism to TLR9 is applied to other intracellular, nucleotide-sensing TLRs.

**SI Materials and Methods**

**Plasmids and Viral Vector Construction.** Mouse TLR9-myc cDNA was a kind gift from Melanie Brinkmann (Whitehead institute for Biomedical Research, Cambridge, MA). C-terminal myc was replaced with HA-Flag tag by a PCR-based method. The amplified fragment was inserted to pENTR1A (Invitrogen) and the sequence was verified. Human Unc93b1 cDNA was purchased from Open Biosystems and cloned into pENTR1A. The subcloned cDNA was transferred to pAd/CMV/V5-DEST (Invitrogen) using the Gateway system (Invitrogen). Adenovirus was generated using ViralPower Adenoviral Expression System (Invitrogen) as described by the manufacturer, following purification using Vivapure AdenoPACK (Satorius Stedim Biotech). TLR9-HA-Flag was subcloned to pWPXL (Addgene) by normal restriction enzymatic method, and then lentiviral particles were generated in 293T cells by calcium-phosphate precipitation transfection with pCMVdelta8.2 and pMD2.G.

**RNAi.** To knockdown Unc93b1, lentiviral particles derived from the pLKO.1-puro–containing the shRNA sequence (TRCN0000173466) were purchased from the Mission shRNA library (Sigma). The shControl was purchased from Sigma. RAW264.7 cells were infected with the lentiviral particles in the presence of 8 μg/mL polybrene. Puromycin (5 μg/mL Invitrogen) was used for selection. To knock down Myd88, cardiomyocytes were transfected with siRNAs (5 nM) using lipofectamine RNAi MAX (Invitrogen) 4–6 h after isolation; Myd88-1 (sense: aggagagcaauuuuugauuTT; antisense: uuaaauaaaguggcucucctT), Myd88-2 (sense: ccuguuguugguaTT; antisense: uuaccuuacaaacagcTT) (Ambion). As a negative control, siControl (Ambion) was used.

**Langendorff Perfusion.** Mice were anesthetized with ketamine (100 mg/mL) and xylazine (20 mg/mL) mixture (2:1; 1.5 μL/g of body weight (BW), intraperitoneally) and heparinized (heparin sodium, 1 IU/g of BW, intraperitoneally). Following a thoracotomy, the heart was excised and rapidly transferred to ice-cold Krebs–Henseleit buffer (KHB), containing (in millimoles) NaCl 118, KCL 3.8, MgSO4 1.19, NaHCO3 25, CaCl2 1.25, KH2PO4 1.18, sodium pyruvate 5, and glucose 10; equilibrated with 95% O2/5% CO2 (pH 7.4). Aortic cannulation was performed (within 1 min of excision), and hearts were perfused with filtered KHB gassed continuously with 95% O2/5% CO2 and maintained at 37 °C. Hearts were retrogradely perfused in a recirculating Langendorff mode. Coronary flow was monitored and adjusted using a flow meter to achieve a coronary perfusion pressure of 75 ± 5 mmHg. Hearts were allowed to stabilize for at least 15 min before any experimental protocols were carried out. A handmade balloon connected to a polyethylene tube was inserted into the left ventricle (LV) through the mitral valve via an incision in the left atrium and was connected to a pressure transducer (AD Instruments). Recorded waveforms were analyzed using chart 5 (AD Instruments) and maximal rate of pressure rise (LV dp/dt max) were calculated from the average of at least 50 cardiac cycles. LV dp/dt max is a reasonable index of the contractile ability of the heart.

**Hypoxia and Cell Viability Assay.** Hypoxia (<1% oxygen for 16 h) was achieved using a hypoxic chamber (Beckton Dickinson), which caused 52% cardiomyocyte death. Cell viability was assessed with MTT assay. Briefly, after hypoxia or H2O2, the medium was changed to medium containing MTT (0.4 mg/mL) and incubated for 60 min at 37 °C. After removal of the MTT medium, DMSO was added, and solubilized formazan was measured at 550 nm with a microplate reader. The cells with normoxia throughout the experiment or without H2O2 were regarded as 100% viable.

**Cytotoxicity Assay.** The differentiated neuronal cells in a 24-well format with neurobasal medium including B27 supplement were pretreated with or without CpG-ODN (type B; 3 μM for 30 min), then incubated with H2O2 (25 μM) for 24 h. Collected supernatants were subjected to lactate dehydrogenase assay (Sigma). Cells without H2O2 were lysed with 1% Triton X-100, regarded as 100% cells dead.

**Confocal Microscopy.** Cardiomyocytes or RAW264.7 cells were plated onto laminin or fibronectin-coated eight-well chamber slides (Nunc) or glass-bottom dishes (Iwaki). Cells were then stimulated with or without CpG-ODN, washed with PBS, and fixed with 4% paraformaldehyde at room temperature for 10 min. After washing with PBS, cells were permeabilized with 0.1% Triton X-100 and blocked with 5% goat serum or 1% BSA. Primary antibodies were then applied and incubated at 4 °C overnight. After labeling with
Alexa 488- or 555-conjugated secondary antibody or streptavidin (Invitrogen), images were obtained using LSM 710 confocal microscopy (Zeiss) with 1 µm thickness using 63× objective lens. At least 20 cells were examined per condition and representative images were chosen.

Measurements of Energy Substrates in the Heart Using High Performance Liquid Chromatography. All measurements of metabolite concentrations were performed using high performance liquid chromatography (HPLC) as described previously (6). The AMP/ATP ratio was calculated from phosphocreatine, creatine, and ATP concentrations as described earlier assuming constant pH and Mg2+ concentration (7).

Intracellular ATP Measurement. Intracellular ATP levels were measured using ATP Bioluminescence Assay kit HS II (Roche), according to the manufacturer’s instructions. Values were normalized by the average of the control cells.

Mitochondrial DNA Extraction and Purity Check. Mitochondrial DNA was isolated from female Wistar rat hearts using a mitochondria isolation kit (Thermo Scientific), according to the manufacturer’s instructions, followed by the DNeasy kit (Qiagen). Extracted DNA was tested for its purity by PCR using genomic (Thr9 locus, 5’-tagctgagaagaaacctgtg-3’ and 5’-cagcttgttattacaccggc-3’) or mitochondrial (CytB; 5’-gattttcatcagtcacccag-3’ and 5’-gattgtctctgtggttgt-3’) primer sets.

ELISA and Western Blotting. For ELISA, cells were treated with CpG-ODN (type B; 3 µM) for 16 h. For cardiomyocytes, 24 h after transfection of YFP or Une93b1 in addition to TLR9-HA-Flag adenoviruses, cells were treated with CpG-ODN. The collected supernatant was analyzed using rat or mouse IL-6 and TNFα-specific ELISA kits (R&D and eBioscience). For Western blotting, cells were washed with PBS and directly lysed with SDS/PAGE sample buffer to inhibit phosphatases and proteins during cell lysis.

Semiquantitative RT-PCR and Real-Time PCR. Total RNA was prepared using RNaseasy kits (Qiagen) with DNase I treatment and compared using RNeasy kits (Qiagen) with DNase I treatment and converted to cDNA with random primers using High Capacity cDNA Reverse Transcription kits (Applied Biosystems) according to the manufacturer’s instructions. After optimization of at least three different PCR cycles, the amplified samples in electrophoresis were assessed by densitometry. Real-time PCR was performed using SYBR green with RG-6000 (Corbett) and comparative quantitation was made as previously described (8). All samples were measured in duplicate. The level of each expression was normalized with beta-2 microglobulin (β2m) (semiquantitative) ubiquitin C (Ubc) (real-time PCR) as housekeeping genes. The primers used in this study are shown in Fig. S8.

Nuclear/Cytosolic Fraction and NF-κB Electrophoretic Mobility Shift Assay. NF-κB electrophoretic mobility shift assay was performed as previously described (9).

Nuclear extracts were harvested from 5 × 106 cells. Briefly, cells were washed in ice-cold PBS and resuspended in 200 µL of buffer A (10 mM Hepes, pH 7.9, 10 mM KCI, 0.1 mM EDTA, 1 mM DTT plus a mixture of protease inhibitors). After 10 min on ice, cells were lysed by addition of Nonident P-40 in a final concentration of 0.1%, and lysates were spun down for 1 min. Cell pellets were washed with 200 µL of buffer A and then resuspended in 50 µL of buffer B (20 mM Hepes, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM DTT plus a mixture of protease inhibitors) for 60 min. The supernatants containing the nuclear fractions was then collected by centrifugation for 5 min at 13,000 × g, then subjected to further analysis. The nuclear extract (7.5 µg) from cardiomyocytes or RAW264.7 cells was incubated with [32P end-labeled, double-stranded oligonucleotide probes in the binding buffer [10 mM Tris pH (7.5), 50 mM NaCl, 1 mM EDTA, 3 mM GTP, 5% glycerol, 1 mg/mL albumin, 0.1 mg/mL poly (dI:dC) and 1 mM DTT], and fractionated in a 4% polyacrylamide gel. The NF-κB double-stranded oligonucleotide probe was purchased from Promega.

NF-κB Luciferase Assay. NF-κB luciferase assay was performed as previously described (10). Briefly, neonatal cardiomyocytes and RAW264.7 cells were transfected with NF-κB-luciferase reporter plasmid and Renilla luciferase plasmid for transfection control by using electroporation (Amaza; Nucleofector) according to the manufacturer’s instructions. Using GFP-expressing construct, we confirmed ∼40% of cardiomyocytes were transfected with this method. Cells were treated for 3 h with the CpG-ODN. After cell lysis, NF-κB stimulation was measured through luciferase activity. Relative light units were calculated in reference to luciferase activity of medium alone.

Statistical Analysis. The comparison between two groups was made by t test (two tailed), and other comparisons were made by ANOVA followed by Bonferroni’s post hoc test. Time-lapse data were assessed by two-way ANOVA repeated measure followed by Bonferroni’s post hoc test. A value of P <0.05 was considered statistically significant. Error bars indicate SEM.


Shintani et al. www.pnas.org/cgi/content/short/1219243110 2 of 7
Fig. S1. Supporting data for Fig. 1. (A) CpG-ODN significantly decreased cardiac contractility (LV dp/dt max) through TLR9 without changing coronary flow. Percent changes from baseline at 30 min after the administration of CpG-ODN are shown. n = 6 (WT), and 5 (TLR9−/−) for each group. Mean ± SEM, *P < 0.05 vs. control vehicle group. NS, not significant. (B) Expression of Tlr9 in rat primary cardiomyocytes. DNaseI-treated total RNA (1 μg) was subjected to conventional RT-PCR. Ubiquitin C (Ubc) was used for internal control. nCM, neonatal cardiomyocyte; cCFb, neonatal cardiac fibroblasts; aCM, adult cardiomyocytes. (C) Mitochondrial DNA (mt; 10 μg/mL) also activated AMPK in cardiomyocytes 60 min after administration. The data represent two independent experiments. The extracted mtDNA was positive for CytB (mitochondria DNA) but not for the genomic DNA (Tlr9 locus). P, positive control for each primer set; N, water. *P < 0.05, **P < 0.01, ***P < 0.001 compared with vehicle control. (D) Knockdown of Myd88 (MyD88-1 and MyD88-2) did not inhibit TLR9-mediated AMPK activation in rat neonatal cardiomyocytes. The data represent three independent experiments.
Fig. 52. Supporting data for Fig. 1. (A) CpG-ODN did not induce phosphorylation or degradation of IκBα in cardiomyocytes. Data represent two different experiments. (B) NF-κB p65 subunit in the nuclear fraction increased at 30 and 60 min after TLR9 stimulation in RAW264.7 cells (RAW), but not in cardiomyocytes (CM). Data represent three different experiments. (C) NF-κB p65 subunit translocated from the cytosol to the nucleus in RAW264.7 cells (RAW) assessed with immunofluorescence, but this was not observed in cardiomyocytes (CM). (Scale bars, 10 μm.) (D) Electrophoretic mobility shift assay showing NF-κB/DNA-binding activity increased after stimulation with CpG-ODN in RAW264.7 cells (RAW), but not in cardiomyocytes (CM). Data represent three different experiments. NS, nonspecific binding. (E) Luciferase assay demonstrated there was no increase in NF-κB transcriptional activity in cardiomyocytes (CM) at the indicated time points, in contrast to significant induction in RAW264.7 cells (RAW). (n = 6 for each group). Error bars indicate SEM. Data represent two different experiments. (F) CpG-ODN administration induced cytokine production (TNF-α and IL-6) in RAW264.7 cells (RAW) and cardiac fibroblasts (CFb), but not in cardiomyocytes (CM). Cells were treated with CpG-ODN (typeB; 3 μM) for 16 h (n = 3 for each group). Error bars indicate SEM. Data represent two different experiments. *P < 0.05 compared with the vehicle control.
**Fig. S3.** Supporting data for Fig. 2. (A) Semiquantitative RT-PCR screening of TLR9 signaling molecules between RAW264.7 \((n = 3)\) and mouse neonatal cardiomyocytes \((n = 5)\). Unc93b1 was significantly less expressed in cardiomyocytes than in RAW264.7 cells. Comparison was made by \(t\) test with statistical difference accepted when \(P < 0.05\). \(*P < 0.05\) compared with RAW264.7 cells. (B) Validation of shRNA for Unc93b1 in RAW264.7 cells. Expression of Unc93b1 was measured by real-time PCR in RAW264.7 cells transfected with the control or shRNA specific for Unc93b1. (C) Unc93b1 knockdown reduced inflammatory response. \(2.5 \times 10^5\) of either control or Unc93b1 shRNA-transfected RAW264.7 cells were plated in 24-well plates, then treated with CpG-ODN \((\text{typeB; } 3 \mu M)\) for 2 h. Collected supernatant was measured by TNF-\(\alpha\) ELISA. Error bars indicate SEM. \(n = 3\) for each group. Data represent two different experiments. \(*P < 0.05\).

**Fig. S4.** Supporting data for Fig. 4. (A) Distribution of biotin-labeled CpG-ODN (green) in RAW264.7 cells were punctate pattern, which was different from the pattern in cardiomyocytes and did not merge with the ER marker \((\text{SERCA2; red})\) 30 min after administration. Images were obtained with confocal microscopy. (B) Endocytosed CpG-ODN localized in the ER in cardiomyocytes. Please note a different distribution pattern from that in RAW264.7 cells. Both cardiomyocytes and RAW264.7 cells were labeled with ER tracker dye \((\text{red})\), then incubated with FITC-labeled CpG-ODN1668 \((3 \mu M)\) for 30 min. Images were obtained with fluorescent microscopy. (Scale bars, 10 \(\mu m\).) Experiments were repeated at least twice and the representative images are shown.
Fig. S5. Supporting data for Fig. 4. (A) The distribution of biotin-labeled CpG-ODN (green) in control RAW264.7 cells was punctate pattern. Endocytosed CpG-ODN merged with endosome marker, EEA1 (red; Upper), but did not merge with the ER marker (SERCA2; red, Lower) 30 min after administration. (B) In contrast, endocytosed CpG-ODN (green) became spread and less punctate in Unc93b1 knocked-down RAW cells. Images were obtained with confocal microscopy. (Scale bars, 10 μm.) The data represent three different experiments and the representative images are shown.

Fig. S6. Supporting data for Fig. 5. Endocytosed CpG-ODN localized in the ER in neuronal cells. Differentiated SHSY5Y cells were labeled with ER tracker dye (red), then incubated with FITC-labeled CpG-ODN1668 (3 μM) for 30 min as in Fig. S4B. (Scale bars, 10 μm.) Experiments were repeated at least twice and the representative images are shown.

Fig. S7. (A) Although there was no AMPK activation at 60 min after TLR2 (HKLM) or TLR4 (LPS-EB) stimulation at the indicated concentrations, TLR7 stimulation (imiquimod) increased the phosphorylation level of AMPK. (B) Pretreatment with nonspecific NO synthase inhibitor, L-NAME (10^{-3} M, 30 min), did not inhibit the TLR9-mediated AMPK activation. Experiments were repeated at least twice and the representative images are shown.
<table>
<thead>
<tr>
<th>Rat</th>
<th>forward primer</th>
<th>reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unc93b1</td>
<td>5'-GCCCTCTTTGCTCTCTACCAA</td>
<td>5'-TCTGGGACATCATGTGTTGATA</td>
</tr>
<tr>
<td>MyD88</td>
<td>5'-ACCAAGTTTTGTCTCTACGCT</td>
<td>5'-GCCAGATAGCTGATGAAACCGT</td>
</tr>
<tr>
<td>TLR9</td>
<td>5'-CTAGACGTTGAGAAGCAACCCCTCTG</td>
<td>5'-CAGCTGTTTATACACCCGATCGGC</td>
</tr>
<tr>
<td>Ubc</td>
<td>5'-CGCTGACAATGCAGATCITT</td>
<td>5'-CTTGTCCTGGATCTTTGCTT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mouse</th>
<th>forward primer</th>
<th>reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unc93b1</td>
<td>5'-AACGCTACTACAGCTGTG</td>
<td>5'-TCTGGGACATCATGTGTTGATA</td>
</tr>
<tr>
<td>IRF3</td>
<td>5'-AGGAAACATGGGAGTTCGAG</td>
<td>5'-CAGTGTCAATGTCAAGCTGTCG</td>
</tr>
<tr>
<td>IRF7</td>
<td>5'-GAGCAGAGACGGGTGGTTACGA</td>
<td>5'-ATGATGGTCACATACCGAAAA</td>
</tr>
<tr>
<td>TRAF6</td>
<td>5'-GTGGAGTTTGGACCCACCTCT</td>
<td>5'-TGCAATCCCTTTAGGATTTGA</td>
</tr>
<tr>
<td>MyD88</td>
<td>5'-TGTTGTGGATGTTTGTGAGAT</td>
<td>5'-GGAAAGTCTTCTTCTTCAGCG</td>
</tr>
<tr>
<td>B2MG</td>
<td>5'-CCTTCAGCAAGGACTGGTCT</td>
<td>5'-TGTCCTGAACCTGAGTACAG</td>
</tr>
<tr>
<td>IRAK4</td>
<td>5'-TCAGAGCCCAGAACAAACAGG</td>
<td>5'-GCTGTCGAGATTGTGTGGT</td>
</tr>
<tr>
<td>TAK1</td>
<td>5'-GTCTGCCCTCTCTGTCTTCTG</td>
<td>5'-CTCTCCGACACCTGCTCTCC</td>
</tr>
<tr>
<td>TAB1</td>
<td>5'-CTGAGCAGACTAGTGCGGTAT</td>
<td>5'-TCTCAGCTAGGCACATGACG</td>
</tr>
<tr>
<td>TAB2</td>
<td>5'-CCCAAGAGTCAAAGGTTCCAC</td>
<td>5'-CGAGGCAATCTCACACTGTC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Human</th>
<th>forward primer</th>
<th>reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unc93b1</td>
<td>5'-ACTACAAGGAGCAAGGAGGATGG</td>
<td>5'-AAGCTCAAGTAGGGAAGAAGCTG</td>
</tr>
<tr>
<td>TLR9</td>
<td>5'-GCAGCTACCATCCCCCTACACCT</td>
<td>5'-GTTCCTGATCCAGGGTCACGA</td>
</tr>
<tr>
<td>Ubc</td>
<td>5'-TCTGTTTTGGATGATCGCTG</td>
<td>5'-TCCAGGGTGATGCTTCTTACC</td>
</tr>
</tbody>
</table>

**Fig. S8.** PCR primers used in this study.